依非韦伦在一名肥胖的HIV感染患者中的应用——一份报告及体外-体内外推模型提示用药剂量不足风险
Efavirenz in an obese HIV-infected patient--a report and an in vitro-in vivo extrapolation model indicate risk of underdosing.
作者信息
de Roche Mirjam, Siccardi Marco, Stoeckle Marcel, Livio Françoise, Back David, Battegay Manuel, Marzolini Catia
机构信息
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
出版信息
Antivir Ther. 2012;17(7):1381-4. doi: 10.3851/IMP2107. Epub 2012 Apr 24.
Here, we report suboptimal efavirenz exposure in an obese patient treated with the standard 600 mg dose. Tripling the dose allowed attainment of therapeutic efavirenz concentrations. We developed an in vitro-in vivo extrapolation model to quantify dose requirements in obese individuals. Obesity represents a risk factor for antiretroviral therapy underdosing.
在此，我们报告了一名接受标准600毫克剂量治疗的肥胖患者中依非韦伦暴露不足的情况。将剂量增加两倍可使依非韦伦达到治疗浓度。我们建立了一个体外-体内外推模型来量化肥胖个体的剂量需求。肥胖是抗逆转录病毒治疗剂量不足的一个危险因素。
Zotero 插件